Claims
- 1. A compound of the formula: ##STR14## a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof,
- wherein:
- X represents hydroxyC.sub.1-6 alkyl, aminocarbonyl, or mono- or di(C.sub.1-6 alkyl)amino-carbonyl;
- Ar represents phenyl, optionally substituted with up to 3 substituents each independently selected from the group consisting of hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, halo, trifluoromethyl, C.sub.1-6 alkylcarbonyl, mono- and di(C.sub.1-6 alkyl)aminocarbonyl, aminocarbonyl, C.sub.1-6 alkyloxycarbonyl, nitro, cyano, amino, aminomethyl, mono-and di(C.sub.1-6 alkyl)amino, (C.sub.1-6 alkylcarbonyl)amino,(aminocarbonyl)amino, and phenylmethoxy;
- provided that when X represents aminocarbonyl, then Ar represents other than 2,6-dihalophenyl substituted in the 4-position with amino, mono- and di(C.sub.1-4 alkyl)amino, C.sub.1-4 alkylcarbonylamino, aminocarbonylamino, C.sub.1-4 alkylcarbonyl, aminocarbonyl, cyano, or halo;
- --(CH.sub.2).sub.n -- represents a bivalent radical wherein n represents 3 or 4 and wherein one hydrogen in said bivalent radical may be replaced by C.sub.1-6 alkyl; and
- Q' represents 2,2-dihalophenylethenyl or 2,2-dihalophenylethyl; provided that Q' represents other than 2,2-di(halophenyl)ethyl when Ar represents dihalophenyl and X represents aminocarbonyl.
- 2. The compound of claim 1 wherein the variable X represents aminocarbonyl, N-methylaminocarbonyl, or N,N-dimethylaminocarbonyl.
- 3. The compound of claim 1 wherein the variable Q' represents 2,2-di(fluorophenyl)ethyl or 2,2-di(fluorophenyl)ethenyl.
- 4. The compound of claim 1 wherein the variable Ar represents phenyl, chloro-substituted phenyl, methylcarbonyl-substituted phenyl, amino-substituted phenyl, N,N-dimethylamino-substituted phenyl, cyano-substituted phenyl, or (aminocarbonyl)amino-substituted phenyl.
- 5. The compound of claim 1 wherein the compound is selected from the group consisting of:
- 3-(aminocarbonyl)-4-[5,5,bis(4-fluorophenyl)-4-pentenyl]-N-(2,6-dichlorophenyl)-1-piperazineacetamide;
- 2-(aminocarbonyl)-4-[5,5,bis(4-fluorophenyl)pentyl]-N-(2,6-dichloro-4-[(dimethylamine)carbonyl]phenyl)-1-piperazineacetamide;
- 3-(aminocarbonyl)-4-[5,5,bis(4-fluorophenyl)pentyl]-N-(4-hydroxy-2,6-dimethylphenyl)-1-piperazineacetamide; and
- 2-(aminocarbonyl)-N-(2,6-dichlorophenyl)-4-(5,5-diphenylpentyl)-1-piperazineacetamide.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of application Ser. No. 419,349, filed on Oct. 10, 1989, now U.S. Pat. No. 4,968,684, which was a continuation of application Ser. No. 165,965, filed on Mar. 9, 1988, now U.S. Pat. No. 4,880,808, which was a continuation-in-part of application Ser. No. 34,129, filed Apr. 1, 1987, now abandoned.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
3267104 |
Hermans et al. |
Aug 1966 |
|
4766125 |
Van Daele |
Aug 1988 |
|
4880808 |
Van Daele et al. |
Nov 1989 |
|
4968684 |
Van Daele et al. |
Nov 1990 |
|
Non-Patent Literature Citations (4)
Entry |
Schaper et al., the Journal of Pharmacology and Experimental Therapeutics, vol. 152, No. 2, 1966, pp. 265-274. |
Ver Donck et al., Chem. Abst. 106-207409t (1987). |
Wauquior et al., Chem. Abst. 106-207546k (1987). |
Van Daele, Chem. Abst. 99-22493j (1983). |
Continuations (2)
|
Number |
Date |
Country |
Parent |
419349 |
Oct 1989 |
|
Parent |
165965 |
Mar 1988 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
34129 |
Apr 1987 |
|